LINC01132 overexpression drives cell growth, proliferation, invasion, and metastasis by interacting with NRF1 to upregulate DPP4. Silencing LINC01132 induces CD8+ T cell infiltration, enhancing anti-tumor immunity when combined with anti-PD-L1 therapy. Here, CD8A is linked to neoplasm.